Description
Molecular imaging techniques include nuclear medicine imaging – positron emission tomography (PET) and single photon emission computed tomography (SPECT) and combination PET/CT and SPECT/CT techniques – as well as ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) imaging that are used with molecular imaging agents.
Molecular imaging has evolved into a pillar of molecular medicine. It combines functional imaging with structural imaging so that specific in-vivo molecular processes can be identified and spatially pinpointed, often with the use of imaging contrast agents that bind to specific biological proteins. Molecular imaging is undertaking diagnostic and treatment roles as it enables physicians to pinpoint the locations of disease and track the progress of therapies. The same contrast agents used to highlight disease sites may even be able to carry drugs that can be selectively unleashed precisely where they are needed.
Medical Imaging Markets: Molecular Imaging offers complete market coverage of world markets for molecular imaging products for the following technologies:
- PET
- SPECT-Gamma Camera Systems
- MRI
- CT
- Ultrasound
- SPECT/CT
- PET/CT
For each of these modalities, the report provides current market size based on revenues to manufacturers of imaging systems used for molecular procedures, as well as forecasts of future revenues.
Interest in and use of the technology has exploded in recent years, thanks to advances in cell biology, biochemical agents, and computer analysis, and serious market watchers in medical imaging industries, as well as those serving or investing in medical imaging companies, will want to keep abreast of this new market. As part of its comprehensive coverage, Medical Imaging Markets: Molecular Imaging includes:
- Overview and Explanation of modalities and key applications
- Over 34 Figures and Tables to make market data accessible to users
- Review of Imaging Agents in Clinical Trials, or that are recently introduced
- Market Size and Forecasts are developed through 2015
- Profiles of Top Competitors in the industry
- Breakout of Regional Markets for Molecular Imaging – including BRIC markets
Kalorama looks at the technologies currently used in molecular imaging but also examines novel research areas, such as:
- Diagnosing Fever of Unknown Origin
- Determine Malignancy in Potential Ovarian Cancer
- PET/CT Impacts Brain Tumor Management
- Improving Care for Neuroendocrine Cancer
- PET Optimizes Virtual Colonoscopy
- Staging Prostate Cancer
- Cyclotron Expansion
- Breast Cancer Screening
- PET Indicates Therapy Effectiveness
- Lower Dosage in Hybrid Imaging
- Analyze Differences in Biochemical Status of Tissues
- Myocardial Flow Reserve Analysis
Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key companies. The market data provide multiple year forecasts for different product segments covered in the report. The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with company executives, clinicians and researchers.
The general aging of the population continues to build the need for diagnosticimaging services. While the aging population is one trend likely to affect imagingprocedure volumes, the behavioral and lifestyle trends of the world population are alsolikely to increase the need for imaging procedures. One example involves obesity, which is often linked to increased risks of cardiovascular disease, diabetes, hypertension, and other illnesses. Imaging is well suited to the diagnosis and management of many age-related diseases such as cardiovascular, cancer, inflammatory and neurological diseases. These diseases are becoming increasingly prevalent as the percentage of elderly people in the population rises. In the US, cancer and cardiovascular disease kill nearly 2 million people each year. According to the American Heart Association
Companies covered in this report include
- ABT Molecular Imaging Inc.
- Advanced Cyclotron Systems Inc.
- Aspect Imaging
- Avid Radiopharmaceuticals Inc.
- Bioscan
- Cardinal Health
- Digirad Corp.
- Dilon Diagnostics
- Gamma Medica Inc.
- GE Healthcare .
- Imaging Diagnostic Systems Inc.
- MIR Preclinical Services
- OptoSonics Inc.
- Philips Healthcare
- Photo Diagnostic Systems
- Positron Corp.
- Shimadzu Corp.
- Spectrum Dynamics Ltd.
- Toshiba America Medical Systems
- UltraSPECT Ltd.
- VisEn Medical
- Zecotek Photonics Inc. Unit 1120
Table of Contents
1.0 EXECUTIVE SUMMARY
1.1 Molecular Basis of Cell Function
1.1.1 Personalized Medicine
1.2 Driving Health Care
1.3 Multicapabilities
1.4 The Power of Imaging
1.4.1 Key Modalities
1.5 World Market Summary
1.5.1 Market Drivers and Challenges
1.5.2 Growth Analysis
1.6 Methodology
2.0 INTRODUCTION
2.1 Definition
2.1.1 Visualizing Biological Events
2.1.2 For Diagnosis and More
2.1.3 Molecular Agents
2.2 New Direction for Medicine
2.3 Modalities and Applications
2.3.1 Nuclear Medicine
2.3.1.1 PET
2.3.1.1.1 Understanding Disease Mechanisms
2.3.1.2 SPECT and Gamma Cameras
2.3.3 MRI
2.3.4 Ultrasound
2.3.5 Fusion Imaging
2.3.5.1 Dual-Modality Advantages
2.3.5.2 PET/CT
2.3.5.3 SPECT/CT
2.3.5.4 PET/MRI
2.3.5.4.1 Therapeutic Successes
2.3.6 Optical Imaging
2.4 Drivers
2.4.1 Complementary Opportunities
2.4.2 Preventive Medicine
2.5 Issues and Challenges
2.5.1 Dual modality Issues
2.5.2 Standardization Needed
2.5.3 Addressing Radiopharmaceutical Shortages
2.5.4 Signaling Improvements, Equipment Configurations Needed
2.5.5 Advances in Devices and Software
2.6 Health Care Reform
2.6.1 Utilization Rate
2.6.2 Tax Concerns
3.0 RESEARCH IMPACTING THE MARKET
3.1 Diagnosing Fever of Unknown Origin
3.2 Determine Malignancy in Potential Ovarian Cancer
3.3 PET/CT Impacts Brain Tumor Management
3.4 Improving Care for Neuroendocrine Cancer
3.5 PET Optimizes Virtual Colonoscopy
3.6 Staging Prostate Cancer
3.7 Cyclotron Expansion
3.8 Breast Cancer Screening
3.9 PET Indicates Therapy Effectiveness
3.10 Lower Dosage in Hybrid Imaging
3.11 Analyze Differences in Biochemical Status of Tissues
3.12 Myocardial Flow Reserve Analysis
4.0 MARKETS
4.1 Overview
4.1.1 Growth In Cardiology
4.1.2 Merging Diagnosis and Treatment
4.2 Procedures
4.3 Forecasts
4.3.1 PET
4.3.1.1 PET/CT
4.3.1.1.1 Time of Flight Impact
4.3.2 SPECT-Gamma Camera Systems
4.3.2.1 SPECT/CT
4.3.2.1.1 Driven by Cardiology
4.3.3 MRI
4.3.4 CT
4.3.5 Ultrasound
5.0 CORPORATE PROFILES
5.1 ABT Molecular Imaging Inc.
5.2 Advanced Cyclotron Systems Inc.
5.3 Aspect Imaging
5.4 Avid Radiopharmaceuticals Inc.
5.5 Bioscan
5.6 Cardinal Health
5.7 Digirad Corp.
5.8 Dilon Diagnostics
5.9 Gamma Medica Inc.
5.10 GE Healthcare
5.11 Imaging Diagnostic Systems Inc.
5.12 MIR Preclinical Services
5.13 OptoSonics Inc.
5.14 Philips Healthcare
5.15 Photo Diagnostic Systems
5.16 Positron Corp.
5.17 Shimadzu Corp.
5.18 Siemens Healthcare
5.19 Spectrum Dynamics Ltd.
5.20 Toshiba America Medical Systems
5.21 UltraSPECT Ltd.
5.22 VisEn Medical
5.23 Zecotek Photonics Inc. Unit 1120
LIST OF EXHIBITS
1.0 EXECUTIVE SUMMARY
Exhibit 1: World Market for PET, 2011-2015
Exhibit 2: World Market for SPECT, 2011-2015
Exhibit 3: World Market for Molecular CT, 2011-2015
Exhibit 4: World Market for Molecular MRI, 2011-2015
Exhibit 5: World Market for Molecular Ultrasound, 2011-2015
Exhibit 6: World Market for PET/CT, 2011-2015
Exhibit 7: World Market for SPECT/CT, 2011-2015
2.0 INTRODUCTION
Exhibit 8: Key Radionuclides
4.0 MARKETS
Exhibit 9: Worldwide SPECT Procedures, 2012 (Cardio., Cancer, Neuro.)
Exhibit 10: US SPECT Procedures, 2012 (Cardio., Cancer, Neuro.)
Exhibit 11: Worldwide PET Procedures, 2012 (Cardio., Cancer, Neuro.)
Exhibit 12: US PET Procedures, 2012 (Cardio., Cancer, Neuro.)
Exhibit 13: Worldwide Molecular CT Procedures, 2012 (US, EU, ROW)
Exhibit 14: Worldwide Molecular MRI Procedures, 2012 (US, EU, ROW)
Exhibit 15: World Medical Market for PET Systems, 2011-2015
Exhibit 16: World Medical Market for PET Systems by Geographic Segment, 2011-2015 (U.S., Europe, BRIC, Japan, ROW)
Exhibit 17: World Medical Market for PET/CT Systems, 2011-2015
Exhibit 18: World Medical Market for PET/CT Systems by Geographic Segment, 2011-2015 (U.S., Europe, BRIC, Japan, ROW)
Exhibit 19: World Medical Market for PET Systems by Geographic Segment, 2012
Exhibit 20: Worldwide Medical PET Installed Base, 2012 (U.S., World)
Exhibit 21: World Medical Market for SPECT Systems, 2011-2015
Exhibit 22: World Medical Market for SPECT Systems by Geographic Segment, 2011-2015 (U.S., Europe, BRIC, Japan, ROW)
Exhibit 23: World Medical Market for SPECT/CT Systems, 2011-2015
Exhibit 24: World Medical Market for SPECT/CT Systems by Geographic Segment, 2011-2015 (U.S., Europe, BRIC, Japan, ROW)
Exhibit 25: World Medical Market for SPECT Systems by Geographic Segment, 2012
Exhibit 26: Worldwide Medical SPECT Installed Base, 2012
Exhibit 27: World Medical Market for MRI Molecular Imaging Systems, 2011-2015
Exhibit 28: World Medical Market for MRI Molecular Imaging Systems by Geographic Segment, 2011-2015 (U.S., Europe, BRIC, Japan, ROW)
Exhibit 29: World Medical Market for MRI Molecular Imaging Systems by Geographic Segment 2012
Exhibit 30: World Medical Market for CT Molecular Imaging Systems 2011-2015
Exhibit 31: World Medical Market for CT Molecular Imaging Systems by Geographic Segment, 2011-2015 (U.S., Europe, BRIC, Japan, ROW)
Exhibit 32: World Medical Market for CT Molecular Imaging Systems by Geographic Segment, 2012
Exhibit 33: World Medical Market for Ultrasound Molecular Imaging Systems, 2011-2015
Exhibit 34: World Medical Market for Ultrasound Molecular Imaging Systems by Geographic Segment, 2011-2015
Exhibit 35: World Medical Market for Ultrasound Molecular Imaging Systems by Geographic Segment, 2012
